L
Lorenz Trümper
Researcher at University of Göttingen
Publications - 276
Citations - 22696
Lorenz Trümper is an academic researcher from University of Göttingen. The author has contributed to research in topics: Lymphoma & Diffuse large B-cell lymphoma. The author has an hindex of 53, co-authored 260 publications receiving 19534 citations. Previous affiliations of Lorenz Trümper include Deutsche Forschungsgemeinschaft & University of Cologne.
Papers
More filters
Journal ArticleDOI
Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
Simone Ferrero,Alessandro Pastore,Christian Scholz,Roswitha Forstpointner,Antonio Pezzutto,Lothar Bergmann,Lorenz Trümper,Jürgen Finke,Ulrich Keller,Paola Ghione,Roberto Passera,Wolfgang Hiddemann,Oliver Weigert,M. Unterhalt,M. Dreyling +14 more
TL;DR: Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
Journal ArticleDOI
Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA).
Gerhard Held,Lorenz Thurner,Viola Poeschel,Christian Berdel,German Ott,Christian Schmidt,Andreas Viardot,Peter Borchmann,Ofer Shpilberg,Maike Nickelsen,Massimo Federico,Peter de Nully Brown,Niels Murawski,Lorenz Trümper,Heinz Schmidberger,Christian Ruebe,Jochen Fleckenstein,Norbert Schmitz,Markus Loeffler,Marita Ziepert,German Lymphoma Alliance +20 more
TL;DR: This data indicates that a second line therapy is urgently needed to treat primary mediastinal B-cell lymphoma in patients with high-risk of developing aggressive lymphoma.
Journal ArticleDOI
Effect of gloved hand disinfection on hand hygiene before infection-prone procedures on a stem cell ward.
Patrick Fehling,Justin Hasenkamp,Steffen Unkel,Ina Thalmann,Sandra Hornig,Lorenz Trümper,Simone Scheithauer +6 more
TL;DR: Gloved hand disinfection significantly improved compliance with the hand hygiene, especially in activities relevant to infections and infection prevention, thus, this process optimization may be an additional easy implementable, resource-neutral tool for a highly vulnerable patient cohort.
Journal ArticleDOI
Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.
Grzegorz S. Nowakowski,Wolfgang Willenbacher,Richard Greil,Thomas Stauffer Larsen,Krish Patel,Ulrich Jäger,Robert Manges,Lorenz Trümper,Corinne Haioun,Hele Everaus,Nagesh Kalakonda,Jeanna Knoble,Peter de Nully Brown,Judit Joergensen,David Cunningham,Neus Domper,Marie-Laure Casadebaig,Oliver Manzke,Javier Munoz +18 more
TL;DR: Results of a phase 2, open-label study of durvalumab (durva) in combination with R- CHOP or R2-CHOP (R-CHop + lenalidomide) in previously untreated, high-risk diffuse large...
Journal ArticleDOI
Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group.
Karin Hohloch,Bettina Altmann,Michael Pfreundschuh,Markus Loeffler,Norbert Schmitz,F. Zettl,Marita Ziepert,Lorenz Trümper +7 more
TL;DR: Obesity is a risk factor that influences treatment outcome in elderly female patients with aggressive B‐cell lymphoma treated with R‐CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone).